

Special Issue

Rho Family of GTPases in Cancer

Message from the Guest Editor

Rho GTPases have emerged as pivotal drivers of cancer metastasis in multiple cancer types. Therefore, understanding their dysregulation in cancer, and developing drugs to inhibit the activation of Rho GTPases has become a priority. Rho GTPases regulate cancer cell motility and invasion, which are a hallmark of metastasis. Even though oncogenic point mutations and splice variants have been reported from a number of cancers, Rho GTPases do not have to be mutated in cancer to drive cancer progression. Much effort has been directed towards drugging the Rho GTPases; however, these drugs have yet to reach clinical trials. This special issue will highlight the current understanding of Rho GTPases in cancer with an emphasis on recognizing their central importance as critical targets for metastatic cancer therapy, for modulation of immunotherapies, and for chemosensitization of current therapeutic strategies.

Guest Editor

Prof. Dr. Suranganie F. Dharmawardhane

Department of Biochemistry, School of Medicine, University of Puerto Rico-Medical Sciences Campus San Juan, Puerto Rico, USA

Deadline for manuscript submissions

closed (31 March 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/28412

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)